The Zhitong Finance App learned that Rezera is a biotech company that is ready to enter phase III clinical trials to develop oral NLRP3 inhibitors for inflammatory diseases. The company filed an IPO application with the US Securities and Exchange Commission (SEC) on Wednesday. The proposed capital raised amount of $100 million (placeholder figure) is set out in the document.

Rezera is developing an oral inhibitor of NLRP3, an upstream driver of aseptic inflammation to treat cardiovascular and neuroinflammatory diseases. NLRP3 Its core drug candidate, ruvonoflast, has completed two phase II trials for cardiometabolic diseases; the company plans to launch a phase III trial for peripheral artery disease (PAD) in the first half of 2027, and the data is expected to be read out in 2028. The company is also developing trabzanoflast, a NLRP3 inhibitor that can pass through the blood-brain barrier, and has completed a phase I trial for neuroinflammatory indications. The company retains a global interest in all drug candidates.

The company was founded in 2016 and plans to list on NASDAQ under the stock symbol RZRA.US. Rezera secretly submitted a listing application on July 7, 2026. Jefferies, TD Securities, and Cantor Fitzgerald acted as joint bookkeepers for this offering, and pricing terms were not disclosed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.